Genomic profiling to detect co-alterations and mutational signatures, and trials to understand the clinical importance of these biomarkers as predictors of response to targeted therapies and immunotherapies in patients with a wide range of KRAS altered tumor types will be imperative to improve therapy selection and outcomes. The gene discussed is KRAS; the disease is neoplasm.